Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 7 No. 1 (2003)

Host Genetics of Tuberculosis Susceptibility

  • Tania Di Pietrantonio
  • Caroline Gallant
  • Erwin Schurr
November 7, 2020




  1. - WHO. Global Tuberculosis Control. WHO Report. Geneva, Switzerland. WHO/CDS/TB/2001.28.
  2. Sreevatsan S, Pan X, Stockbauer KE, Connell ND et al. Restricted Structural Gene Polymorphism in the Mycobacterium tuberculosis Complex Indicates Evolutionarily Recent Global Dissemination. Proceedings of National Academy of Sciences USA 94:9869-9874; 1997.
  3. Maher D, Floyd K, Raviglione M. A Strategic Framework to Decrease the Burden of TB/HIV. WHO Report. Geneva, Switzerland. WHO/CDS/TB/2002.296.
  4. Kaufmann SHE. How Can Immunology Contribute to the Control of Tuberculosis? Nature Reviews Immunology 1:20-30; 2001.
  5. Haldane JBS. Disease and Evolution. Ric Sci (Suppl. A) 68-76; 1949.
  6. Daniel TM, Bates JH, Downes KA. History of Tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994.
  7. Schürmann; Beobachtungen bei den Lübecker Säuglingstuberkulosen; Beit z Klin Tuberk 81: 294; 1932.
  8. Pierce C, Dubos RJ, Middlebrook G. Infection of Mice with Mammalian Tubercle Bacilli Grown in Tween-Albumin Liquid Medium. Journal of Experimental Medicine 86:159-174; 1947.
  9. Medina E, North RJ. Resistance Ranking of Some Common Inbred Mouse Strains to Mycobacterium tuberculosis and Relationship to Major Histocompatibility Haplotype and Nramp1 Genotype. Immunology 93:270-274; 1998.
  10. Lynch CJ, Pierce-Chase CH, Dubos R. A Genetic Study of Susceptibility to Experimental Tuberculosis in Mice Infected
  11. with Mammalian Tubercle Bacilli. Journal of Experimental Medicine 121:1051-1070; 1965.
  12. Musa SH, Kim Y, Hashim R, Wang GZ, Dimmer C, Smith D. Response of inbred mice to aerosol challenge with
  13. Mycobacterium tuberculosis. Infection and Immunity 55:1862- 1866; 1987.
  14. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. New England Journal of Medicine. 338:640-644; 1998.
  15. Abel L, Sanchez FO, Oberti J, et al. Susceptibility to leprosy is linked to the human NRAMP1 gene. Journal of Infectious Diseases 177:133 145; 1998.
  16. Marquet S, Sanchez FO, Arias M et al. Variants of the human NRAMP1 gene and altered human immunodeficiency virus
  17. infection susceptibility. Journal of Infectious Diseases 180:1521-1525; 1999.
  18. Gros P, Skamene E, Forget A. Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. Journal of Immunology. 127:2417-2421; 1981.
  19. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. Natural Resistance to infection with Intracellular Parasites: Isolation of a Candidate for Bcg. Cell 73:469-485; 1993.
  20. Skamene E, Gros P, Forget A, Kongshavn PAL, St. Charles C, Taylor BA. Genetic regulation of resistance to intracellular pathogens. Nature 297:506-509; 1982.
  21. Stach JL. Gros P, Forget A, Skamene E. Phenotypic expression of genetically-controlled natural resistance to Mycobacterium bovis (BCG). Journal of Immunology 132:888-892; 1984.
  22. Medina E, North RJ. Evidence inconsistent with a role for the Bcg gene (Nramp1) in resistance of mice to infection with Mycobacterium tuberculosis. Journal of Experimental Medicine 183:1045-1051; 1996.
  23. North RJ, LaCourse R, Ryan L, Gros P. Consequence of Nramp1 deletion to Mycobacterium tuberculosis infection in mice. Infection and Immunity 67:5811-5814; 1999.
  24. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-42; 1993.
  25. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma genedisrupted mice. Journal of Experimental Medicine 178:2243-2247; 1993.
  26. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. Journal of Experimental Medicine 178:2249-2254; 1993.
  27. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production. Journal of Immunology 141:2407-2412; 1988.
  28. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proceedings of National Academy oF Sciences U S A 94:5243-5248; 1997.
  29. Adams LB, Dinauer MC, Morgenstern DE, Krahenbuhl JL. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tubercle and Lung Disease 78:237-246; 1997.
  30. Bean AG, Roach DR, Briscoe H et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. Journal of Immunology 162:3504-3511; 1999.
  31. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. Journal of Immunology 168:4620- 4627; 2002.
  32. Jacobs M, Brown N, Allie N, Chetty K, Ryffel B. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 68:68-75; 2000.
  33. Flesch IE, Hess JH, Huang S et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Journal of Experimental Medicine 181:1615-1621;1995.
  34. Murphy EE, Terres G, Macatonia SE et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. Journal of Experimental Medicine 180:223-231; 1994.
  35. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. Journal of Experimental Medicine 186:39-45; 1997.
  36. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin18 regulates both Th1 and Th2 responses. Annual Reviews: Immunology 19:423-474; 2001.
  37. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91; 1995.
  38. Sugawara I, Yamada H, Kaneko H, Mizuno S, Takeda K, Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene disrupted mice. Infection and Immunity 67:2585-2589; 1999.
  39. Kinjo Y, Kawakami K, Uezu K, et al. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL12p40. Journal of Immunology 169:323-329; 2002.
  40. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infection and Immunity 68:3322-3326; 2000.
  41. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infection and Immunity 65:4843-4849; 1997.
  42. Juffermans NP, Florquin S, Camoglio L et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. Journal of Infectious 182:902-908; 2000.
  43. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clinical and Experimental Immunology 113:55-58; 1998.
  44. Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infection and Immunity 67:3087-3095; 1999.
  45. Sugawara I, Yamada H, Mizuno S, Iwakura Y. IL-4 is required for defense against mycobacterial infection. Microbiology and Immunology 44:971-979; 2000.
  46. Brett S, Orrell JM, Swanson Beck J, Ivanyi J. Influence of H-2 genes on growth of Mycobacterium tuberculosis in the lungs of chronically infected mice. Immunology 76:129-132; 1992.
  47. Apt AS, Avdienko VG, Nikonenko BV, Kramink IB, Moroz AM. Distinct H-2 complex control of mortality, and immune responses to tuberculosis in virgin and BCG-vaccinated mice. Clinical and Experimental Immunology 94:322-329; 1993.
  48. Brett SJ, Ivanyi J. Genetic influences on the immune repertoire following tuberculosis infection in mice. Immunology 71:113- 119; 1990.
  49. Ivanyi J, Sharp K. Control by H-2 genes of murine antibody responses to protein antigens of Mycobacterium tuberculosis. Immunology 59:329-332; 1986.
  50. Orrell JM, Brett SJ, Ivanyi J, Coghill G, Grant A, Beck JS. Morphometric analysis of Mycobacterium tuberculosis infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Journal of Pathology 166:77-82; 1992.
  51. Darvasi A, Weinreb A, Minke V, Weller JI, Soller M. Detecting marker-QTL linkage and estimating QTL gene effect and map location using a saturated genetic map. Genetics 134:943-951;1993.
  52. Jansen RC. Interval mapping of multiple quantitative trait loci. Genetics 135:205-211; 1993.
  53. Lavebratt C, Apt AS, Nikonenko BV, Schalling M, Schurr E. Severity of tuberculosis in mice is linked to distal chromosome 3 and proximal chromosome 9. Journal of Infectious Diseases 180:150-155; 1999.
  54. Sanchez F, Radaeva TV, Nikonenko BV et al. Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice. Infection and Immunity 71:126-131; 2003.
  55. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proceedings of National Academy of Sciences U S A 97:8560-8565; 2000.
  56. Mitsos M, Cardon LR, Fortin A et al. Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice. Genes and Immunity 1:467-477; 2000.
  57. Abel L, Casanova J-L. Genetic Predisposition to Clinical Tuberculosis: Bridging the Gap between Simple and Complex Inheritance. American Journal of Human Genetics 67:274-277; 2000.
  58. Greenwood CMT, Fujiwara TM, Boothroyd LJ et al. Linkage of Tuberculosis to Chromosome 2q35 Loci, Including NRAMP1, in a Large Aboriginal Canadian Family. American Journal of Human Genetics 67:405-416; 2000.
  59. Jouanguy E, Lamhamedi-Cherradi S, Altare F et al. Partial interferon- receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. Journal of Clinical Investigation 100:2658-2664; 1997.
  60. Picard C, Fieschi C, Altare F et al. Inherited Interleukin-12 Deficiency: IL-12B Genotype and Clinical Phenotype of Thirteen Patients from Six Kindreds. American Journal of Human Genetics 70:336-348; 2002.
  61. Ting L-M, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis Inhibits IFN- Transcriptional Responses Without Inhibiting Activation of STAT1. Journal of Immunology 163:3898-3906; 1999.
  62. Elloumi-Zghal H, Barbouche MR, Chemli J et al. Clinical and Genetic Heterogeneity to Disseminated Mycobacterium bovis Bacille Calmette-Guérin Infection. Journal of Infectious Diseases 185:1468-1475; 2002.
  63. Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432-1435; 1998.
  64. Jounaguy E, Lamhamedi -Cherradi S, Lammas D et al. A human IFNGR1 small deletion associated with dominant susceptibility
  65. to mycobacterial infection. Nature Genetics 21:370-8; 1999.
  66. Jouanguy E, Altare F, Lamhamedi S et al. A human interferon-interferon deficiency in an infant with fatal bacille CalmetteGuérin. New England Journal of Medicine 335:1956-1961; 1996.
  67. Newport MJ, Huxley CM, Huston S et al. A Mutation in the Interferon- -Receptor Gene and Susceptibility to Mycobacterial Infection. New England Journal of Medicine 355:1941-1945; 1996.
  68. De Jong R, Altare F, Haagen I-A et al. Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients. Science 280:1435-1438; 1998.
  69. Dupuis S, Dargemont C, Fieschi C et al. Impairment of Mycobacterial but not Viral Immunity by a Germline Human STAT1 Mutation. Science 293:300-303; 2001.
  70. Ottenhoff THM, Verreck FAW, Lichtenauer-Kaligis EGR, Hoeve MA, Sanal O, van Dissel JT. Genetics, Cytokines and Human Infectious Disease: Lessons from Weakly Pathogenic Mycobacteria and Salmonella. Nature Genetics 32:97-105; 2002.
  71. Casanova JL, Abel L. Genetic Dissection of Immunity to Mycobacteria: The Human Model. Annual Reviews: Immunology 20:581-620; 2002.
  72. Cooke GS, Hill AVS. Genetics of Susceptibility to Human Infectious Disease. Nature Genetics 2:967-977; 2001.
  73. Lio D, Marino V, Serauto A et al. Genotype Frequencies of the +874T-- A Single Nucleotide Polymorphism in the First Intron of the Interferon-Gamma Gene in a Sample of the Sicilian Patients Affected by Tuberculosis. European Journal of Immunogenetics 29:371-374; 2002.
  74. López-Maderuello D, Arnalich F, Serantes R et al. Interferonand Interleukin-10 Gene Polymorphisms in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine 167:970-975; 2003.
  75. Mitsuteru A, Nakashima H, Miyake K et al. Influence of Interleukin-12 Receptor 1 Polymorphisms on Tuberculosis. Human Genetics 112:237-243; 2003.
  76. Malik S, Schurr E. Genetic Susceptibility to Tuberculosis. Clinical Chemisty and Laboratory Medicine 40:863-868; 2002.
  77. Gao P-S, Fujishima S, Mao X-Q et al. Genetic Variants of NRAMP1 and Active Tuberculosis in Japanese Populations. Clinical Genetics 58:74-76; 2000.
  78. Ryu S, Park YK, Bai GH et al. 3'UTR Polymorphisms in the NRAMP1 Gene are Associated with Susceptibility to Tuberculosis in Koreans. International Journal of Tuberculosis and Lung Disease 4:677-580; 2000.
  79. Cervino AC, Lakiss S, Sow O, Hill AV. Allelic Association between the NRAMP1 Gene and Susceptibility to Tuberculosis in Guinea-Conakry. Annals Human Genetics 64:507-512; 2000.
  80. Delgado JC, Baena A, Thim S, Goldfeld AE. Ethnic-Specific Genetic Associations with Pulmonary Tuberculosis. Journal of Infectious Diseases 186:1463-1468; 2002.
  81. Bellamy R. Susceptibility to Mycobacterial Infections: The Importance of Host Genetics. Genes and Immunity 4:4-11; 2003.
  82. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25- dihydroxyvitamin D3: A Novel Immunoregulatory Hormone. Science 224:1438-1440; 1984.
  83. Lemire JM, Adams JS, Sakai R, Jordan SC. 1 ,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobin production by normal human peripheral blood mononuclear cells. Journal of Clinical Investigation 74:657-661; 1984.
  84. Rook GAW, Taverne J, Leveton C, Steele J. The Role of gammainterferon, vitamin D3 metabolites and tumor necrosis factor in the pathogenesis of tuberculosis. Immunology 62:229-234; 1987.
  85. Christakos S, Dhawan P, Liu Y, Peng Xizorong, Porta A. New Insights into the Mechanism of Vitamin D Action. Journal of Cellular Biochemistry 88:695-705; 2003.
  86. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infection and Immunity 66:5314-5321; 1998.
  87. Rook GAW, Steele J, Fraher L et al. Vitamin D3, gamma interferon, and the control of Mycobacterium tuberculosis by human monocytes. Immunology 57:159-163; 1986.
  88. Cadrenel J, Hance AJ, Milleron B, Paillard F, Akoun GM, Garabedian M. The Production of 1,25(OH)2D3 by Cells Recovered by Bronchoalveolar Lavage and the Role of This Metabolite in Calcium Homostasis. American Review of Respiratory Diseases 138:984-989; 1988.
  89. Chan TYK. Vitamin D Deficiency and Susceptibility to Tuberculosis. Calcified Tissue International 66:476-478; 2000.
  90. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 ,25- dihydroxy-vitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proceedings of the National Academy of Sciences USA 84:3385-3389; 1987.
  91. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1 ,25- dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181-1183; 1983.
  92. Bellamy R, Ruwende C, Corrah T et al. Tuberculosis and Chronic Hepatitis B Virus Infection in Africans and Variation in the Vitamin D Receptor Gene. Journal of Infectious Diseases 179:722-724; 1999.
  93. Wilkinson RJ, Llewelyn M, Toossi Z et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis amongst Gujarati Asians in west London. Lancet 355:18-621; 2000.
  94. Sing SPN, Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human Leukocyte Antigen (HLA)-linked Control of Susceptibility to Tuberculosis and Association with HLA-DR Types. Journal of Infectious Diseases 148:676-681; 1983.
  95. Bothamley GH, Beck JS, Schreuder et al. Association of tuberculosis and tuberculosis-specific antibody levels with HLA. Journal of Infectious Diseases 159:549-555; 1989.
  96. Brahmajothi V, Pitchappan RM, Kakkanaiah VN et al. Association of pulmonary tuberculosis and HLA in South India. Tubercle 72:123-132; 1991.
  97. Rajalingam R, Mehra NK, Jain RC, Myneedu VP, Pande JN. Polymerase chain reaction-based sequence-specific oligonucleotide hybridization analysis of the HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. Journal of Infectious Diseases 173:669- 676; 1996.
  98. Teran-Escandon D, Teran-Ortiz L, Carnarena-Olvera A et al. Human Leukocyte Antigen-Associated Susceptibility to Pulmonary Tuberculosis: Molecular Analysis of Class II Alleles by DNA Amplification and Oligonucleotide Hybridization in Mexican Patients. Chest 115:428-433; 1999.
  99. Goldfeld AE, Delgado JC, Thim S et al. Association of an HLADQ Allele with Clinical Tuberculosis. Journal of the American Medical Association 279:226-228; 1998.
  100. Sanjeevi CB, Narayanan PR, Prabakar R et al. No Association or Linkage with the HLA-DR or -DQ Genes in South Indians with Pulmonary Tuberculosis. Tuberulosis and Lung Disease 73:280-284; 1992.
  101. Cox RA, Downs M, Neimes RE, Ognibene AJ, Yamashita TS, Ellner JJ. Immunogenetic analysis of human tuberculosis. Journal of Infectious Diseases 1988; 158:1302-1308.
  102. Arend, WP. The Balance Between IL-1 and IL-Ra in Disease. Cytokine and Growth Factors Review 13:323-240; 2002.
  103. Tsao TC, Hong J, Huang C, Yang P, Liao SK, Chang KS. Increased TNF-alpha, IL-1 beta and IL-6 Levels in the Bronchoalveolar Lavage Fluid with the Upregulation of Their mRNA in Macrophages Lavaged from Patients with Active Pulmonary Tuberculosis. Tuberculosis and Lung Disease 1999; 79:279-285.
  104. Juffermans N, Verbon A, van Deventer H et al. Tumor Necrosis Factor and Interleukin-1 Inhibitors As Markers of Disease Activity of Tuberculosis. American Journal of Respiratory and Critical Care Medicine 157:1328-1331; 1998.
  105. Bellamy R, Ruwende C, Corrah T, McAdam KPWJ, Whittle HC, Hill AVS. Assessment of the Interleukin 1 Gene Cluster and other Candidate Gene Polymorphisms in the Host Susceptibility to Tuberculosis. Tubercle and Lung Disease 1998; 79:83-89.
  106. Havell EA. Evidence that Tumor Necrosis Factor has an Important Role in Antibacterial Resistance. Journal of Immunology 143:2894 2901; 1989.
  107. Denis M. Tumor Necrosis Factor and Granulocyte MacrophageColony Stimulating Factor Stimulate Human Macrophages to Restrict Growth of Virulent Mycobacterium avium and to Kill Avirulent M. avium: Killing Effector Mechanism Depends on the Generation of Nitrogen Intermediates. Journal of Leukocyte Biology 49:380-387; 1991.
  108. Mohan AK, Cote TR, Siegal JN, Braun MM. Infectious Complications of Biologic Treatments of Rheumatoid Arthritis. Current Opinions in Rheumatology 15:179-184; 2003.
  109. Gardam MA, Keystone EC, Menzies R et al. Anti-Tumor Necrosis Factor Agents and Tuberculosis Risk: Mechanisms of Action and Clinical Management. Lancet Infectious Diseases 3:148-155; 2003.
  110. Moraes MO, Duppre NC, Suffys PN. Tumor Necrosis FactorPromoter Polymorphisms TNF2 is Associated with a Stronger Delayed-Type Hypersensitivity Reaction in the Skin of Borderline Tuberculoid Leprosy Patients. Immunogenetics 53:45-47;2001.
  111. Roy S, McGuire W, Mascie-Taylor GN. Tumor Necrosis factor Polymorphism and Susceptibility to Lepromatous Leprosy. Journal of Infectious Diseases 176:530-532; 1997.
  112. Scola L, Crivello A, Marino V, Gioia V et al. IL-10 and TNFalpha Polymorphisms in a Sample of Sicilian Patients Affected by Tuberculosis: Implications for Ageing and Life Spam Expectancy. Mechanisms of Ageing and Development 124:569- 572; 2003.
  113. Bellamy R, Beyers N, McAdam KPWJ et al. Genetic Susceptibility to Tuberculosis in Africans: A Genome-Wide Scan. Proceedings of the National Academy of Science USA 97:8005-8009; 2000.
  114. Cervino AC, Lakiss S, Sow O et al. Fine Mapping of a Putative Tuberculosis-Susceptibility Locus on Chromosome15q11-13 in African families. Human Molecular Genetics 11:1599-603; 2002.
  115. Shaw M-A, Donaldson IJ, Collins A et al. Association and Linkage of Leprosy Phenotypes with HLA Class II and Tumor Necrosis Factor Genes. Genes and Immunity 2:196-204; 2001


Download data is not yet available.